How We Created a Tool That Tells You Where Your Generic Drugs Were Made

For decades, the FDA made it nearly impossible to know which factories were manufacturing your generic medications. ProPublica built a tool to show you. Here’s how we did it.
pharmaphorum

Life Sciences Industry Report - Biologics and Generics

The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems, providing an alternative to comparator products and lowering price ...
pharmaphorum

Could a Novo error set up early GLP-1 generics in Canada?

It has been reported that Novo Nordisk may have inadvertently allowed generics of its GLP-1 agonist semaglutide, the active ingredient in diabetes therapy Ozempic and obesity drug Wegovy, into the ...
STAT

Solicitor general urges Supreme Court to review ‘skinny labeling’ and generic drug access

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
C&EN

Looming GLP-1 drug patent expirations draw generics firms

In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...
Investopedia

Understanding Collection Agencies: Operations and Key Regulations

Julia Kagan is a financial/consumer journalist and former senior editor, personal finance, of Investopedia. Thomas J. Brock is a CFA and CPA with more than 20 years of experience in various areas ...